Safety and Effectiveness of Tofogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: Results of 24-month Interim Analysis of a Long-term Post-marketing Study (J-STEP/LT)

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2020 Feb 9

PMID 32034997

Citations 8

Authors

Kazunori Utsunomiya

Seigo Kakiuchi

Masayuki Senda

Shoko Fujii

Yuji Kurihara

Ryoji Gunji

Ryusuke Koshida

Hiroyuki Kameda

Masahiro Tamura

Kohei Kaku

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: Tofogliflozin is a potent and highly selective sodium-glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3-year study of tofogliflozin in patients with type 2 diabetes mellitus to evaluate the safety and effectiveness in routine clinical practice. The 3- and 12-month interim analysis showed tofogliflozin was well-tolerated, safe and clinically effective. Here, we report the results of the 24-month interim analysis.

Materials And Methods: This is a 3-year prospective, observational and multicenter post-marketing study (Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients/Long Term).

Results: Of the 6,897 patients enrolled, 6,712 and 6,461 patients were analyzed for the safety and effectiveness of tofogliflozin, respectively. During the 24-month observation period, the incidence rates of adverse drug reactions (ADRs) and serious adverse drug reactions were 11.25 and 1.21%, respectively. As to adverse drug reactions of special interest, the incidence rates of hypoglycemia, polyuria/pollakiuria, volume depletion-related events, urinary tract infections and genital infection were 0.83, 1.28, 1.46, 1.18 and 1.62%, respectively. Renal disorders, and cardiovascular and cerebrovascular disorders occurred in 0.63 and 0.76% of the patients, respectively. Glycated hemoglobin A1c and bodyweight decreased significantly by -0.70% (P < 0.0001) and -2.95 kg (P < 0.0001), respectively, from baseline to week 104 (last observation carried forward).

Conclusions: Significant safety concerns have not been observed, and clinical benefit including a long-term reduction in glycated hemoglobin A1c over a 104-week (24 months) observation period with weight loss was suggested in this 24-month interim analysis of the 3-year Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients/Long Term in routine clinical practice.

Citing Articles

Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin-a post-hoc analysis of the UTOPIA study.

Katakami N, Mita T, Sato Y, Watada H, Shimomura I Diabetol Int. 2024; 15(3):379-388.

PMID: 39101158 PMC: 11291786. DOI: 10.1007/s13340-024-00693-x.

Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.

Elian V, Popovici V, Karampelas O, Gradisteanu Pircalabioru G, Radulian G, Musat M Int J Mol Sci. 2024; 25(4).

PMID: 38396657 PMC: 10888162. DOI: 10.3390/ijms25041972.

Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin.

Ito H, Inoue H, Izutsu T, Matsumoto S, Antoku S, Yamasaki T PLoS One. 2023; 18(9):e0292014.

PMID: 37733761 PMC: 10513294. DOI: 10.1371/journal.pone.0292014.

Renal outcomes with sodium-glucose cotransporters 2 inhibitors.

Sun X, Wang G Front Endocrinol (Lausanne). 2022; 13:1063341.

PMID: 36531469 PMC: 9752889. DOI: 10.3389/fendo.2022.1063341.

Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis.

Chen C, Peng H, Li M, Lu X, Huang M, Zeng Y Front Endocrinol (Lausanne). 2021; 12:664533.

PMID: 34759887 PMC: 8572881. DOI: 10.3389/fendo.2021.664533.

References

Poole R, Prossler J . Tofogliflozin: first global approval. Drugs. 2014; 74(8):939-44. DOI: 10.1007/s40265-014-0229-1. View

Kamei S, Iwamoto M, Kameyama M, Shimoda M, Kinoshita T, Obata A . Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus. J Diabetes Res. 2018; 2018:6470137. PMC: 5817268. DOI: 10.1155/2018/6470137. View

Obata A, Kubota N, Kubota T, Iwamoto M, Sato H, Sakurai Y . Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology. 2015; 157(3):1029-42. DOI: 10.1210/en.2015-1588. View

Leiter L, Langslet G, Vijapurkar U, Davies M, Canovatchel W . Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. Diabetes Ther. 2016; 7(2):269-78. PMC: 4900973. DOI: 10.1007/s13300-016-0163-1. View

Utsunomiya K, Senda M, Kakiuchi S, Kameda H, Tamura M, Kurihara Y . Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). J Diabetes Investig. 2019; 10(5):1272-1283. PMC: 6717810. DOI: 10.1111/jdi.13017. View

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K . Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group.... Cardiovasc Diabetol. 2014; 13:65. PMC: 4021346. DOI: 10.1186/1475-2840-13-65. View

Yoshida A, Matsubayashi Y, Nojima T, Suganami H, Abe T, Ishizawa M . Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. J Clin Endocrinol Metab. 2019; 104(9):3647-3660. DOI: 10.1210/jc.2018-02254. View

Rosenwasser R, Rosenwasser J, Sutton D, Choksi R, Epstein B . Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2014; 50(11):739-45. DOI: 10.1358/dot.2014.50.11.2232267. View

Kaneko M, Narukawa M . Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio. Clin Drug Investig. 2018; 39(2):179-186. DOI: 10.1007/s40261-018-0731-4. View

10.

Scheen A . Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet. 2015; 54(7):691-708. DOI: 10.1007/s40262-015-0264-4. View

11.

Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K . Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter,.... Expert Opin Pharmacother. 2014; 15(6):749-66. DOI: 10.1517/14656566.2014.887680. View

12.

Utsunomiya K, Kakiuchi S, Senda M, Fujii S, Kurihara Y, Gunji R . Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT). J Diabetes Investig. 2020; 11(4):906-916. PMC: 7378444. DOI: 10.1111/jdi.13233. View

13.

Davidson J . SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med. 2019; 131(4):251-260. DOI: 10.1080/00325481.2019.1601404. View

14.

Chen L, Liu L, Woo J, Assantachai P, Auyeung T, Bahyah K . Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014; 15(2):95-101. DOI: 10.1016/j.jamda.2013.11.025. View

15.

Carlson C, Santamarina M . Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf. 2016; 15(10):1401-12. DOI: 10.1080/14740338.2016.1216100. View

16.

Sugiyama S, Jinnouchi H, Yoshida A, Hieshima K, Kurinami N, Jinnouchi K . Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center. J Clin Med Res. 2019; 11(4):267-274. PMC: 6436561. DOI: 10.14740/jocmr3761. View

17.

Thomas M, Cooper M, Zimmet P . Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2015; 12(2):73-81. DOI: 10.1038/nrneph.2015.173. View

18.

Nunoi K, Sato Y, Kaku K, Yoshida A, Suganami H . Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. Endocrinol Diabetes Metab. 2019; 1(2):e00015. PMC: 6354802. DOI: 10.1002/edm2.15. View

19.

Ogawa W, Sakaguchi K . Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016; 7(2):135-8. PMC: 4773669. DOI: 10.1111/jdi.12401. View

20.

DeFronzo R, Davidson J, Del Prato S . The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2011; 14(1):5-14. DOI: 10.1111/j.1463-1326.2011.01511.x. View